Use access key #2 to skip to page content.
$0.78 -0.05 (-5.90%)
11/20/2008 11:28 AM

Pharmacopeia, Inc. (PCOP)

CAPS Rating:
**

A biopharmaceutical company committed to discovering and developing novel therapeutics to address medical needs.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

PCOP doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

24 Outperforms
5 Underperforms
 

All-Stars

0 Outperforms
2 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on PCOP are also bullish on:

Members bearish on PCOP are also bearish on:

Ticker Tags

Micro Cap (4896), Biotechnology (230)
Suggest a tag

Pharmacopeia, Inc. At A Glance

Current Price: $0.78
Last Trade Time: 11/20/2008 11:28 AM
Open: $0.90
Previous Close: $0.83
Daily Range: $0.78 - $0.94
52-Week Range: $0.78 - $5.59
Volume: 38,032
Market Cap: $24.79M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

PCOP VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for PCOP

More Headlines...

Top Bull Pitch

Recs

1

Pharmacopeia, Inc. (PCOP)

Avatar FatDanS (20.20) Submitted: 9/05/07 10:33 AM

Taking a risk that they will have a winning compound i the next three years. If so this stock will be through the roof.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 4 of 4  

Recs

0

 (PCOP)

Avatar pvtennis04 (53.01) Submitted: 12/20/07 1:24 AM : Outperform Start Price: $4.80 PCOP Score: -38.18

Expect good results from their DARA hypertension and diabetic nephropathy drug trials in 2008. They also have good strategic alliances with major pharmaceutical companies. Also have several other promising compounds in their pipeline. Two new analysts have initialized coveraged in the past year, could get this stock in the spotlight.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (PCOP)

Avatar myersfield (27.34) Submitted: 9/20/07 2:48 PM : Outperform Start Price: $5.42 PCOP Score: -38.05

Strong partnerships.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (PCOP)

Avatar FatDanS (20.20) Submitted: 9/05/07 10:33 AM : Outperform Start Price: $5.59 PCOP Score: -40.16

Taking a risk that they will have a winning compound i the next three years. If so this stock will be through the roof.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (PCOP)

Avatar dutchburger (61.48) Submitted: 8/27/07 9:53 PM : Outperform Start Price: $5.69 PCOP Score: -40.98

A very promising biotech, providing outsourced R&D for an impressive selection of blue chip farma companies. The stock could jump with just one of their clinical testing programs becoming successful - and they have at least 6 of them.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 4 of 4  

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackBroadpointC < 20 09/27/07 Outperform NS $5.74-86.41%-47.73%-38.68

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links